1. Field of the Invention
The present application relates generally to tissue treatment systems and in particular to a system and method for reduced pressure charging.
2. Description of Related Art
Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a porous pad or other manifold device. The porous pad contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The porous pad often is incorporated into a dressing having other components that facilitate treatment.
Reduced pressure treatment systems may include reduced pressure sources such as a powered pump that generates the reduced pressure that is delivered to a tissue site. However, such reduced pressure sources are often bulky or obtrusive to a user and are not readily adapted to be used in conjunction with foot treatment systems.
The problems presented by existing reduced pressure treatment systems are solved by the systems and methods of the illustrative embodiments described herein. In one illustrative embodiment, a reduced pressure treatment system includes a compressible bladder positioned beneath a foot of a user. The compressible bladder includes a chamber substantially enclosed by a chamber wall, and the compressible bladder is movable between an expanded position and a compressed position to generate a reduced pressure. A resilient member is operatively associated with the chamber wall to bias the compressible bladder toward the expanded position. A manifold is positioned at a tissue site of the user and in fluid communication with the chamber of the compressible bladder.
In another illustrative embodiment, a reduced pressure treatment system is provided. The reduced pressure treatment system includes a compressible chamber positionable beneath a foot of a user and being movable between an expanded position and a compressed position. The compressible chamber includes an inlet and an outlet. An inlet valve is in fluid communication with the inlet to prevent fluid within the compressible chamber from exiting the inlet, and an outlet valve is in fluid communication with the outlet to prevent fluid from entering the compressible chamber through the outlet. A biasing member is disposed within the compressible chamber to bias the compressible chamber toward the expanded position, and a manifold is positionable at a tissue site and in fluid communication with the inlet of the compressible chamber.
In still another illustrative embodiment, a reduced pressure treatment system is provided and includes a compressible bladder positionable beneath a foot of a user. The compressible bladder includes a chamber and is movable between an expanded position and a compressed position. The system further includes a biasing member disposed within the chamber to bias the compressible bladder toward the expanded position. A pressure regulator having a first variable-volume cavity and a second variable-volume cavity is provided. The first variable-volume cavity is fluidly connected to the chamber of the compressible bladder, and a manifold is positionable at a tissue site and in fluid communication with the second variable-volume cavity of the pressure regulator.
In yet another illustrative embodiment, a method for providing a reduced pressure to a reduced pressure tissue treatment system used by a user is provided. The method includes compressing a compressible bladder with a foot of the user and generating the reduced pressure within a chamber of the compressible bladder as the compressible bladder expands.
Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
In the following detailed description of several illustrative embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.
The term “reduced pressure” as used herein generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure reduction applied to the tissue site may be significantly less than the pressure reduction normally associated with a complete vacuum. Reduced pressure may initially generate fluid flow in the area of the tissue site. As the hydrostatic pressure around the tissue site approaches the desired reduced pressure, the flow may subside, and the reduced pressure is then maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in reduced pressure typically refer to a decrease in absolute pressure, while decreases in reduced pressure typically refer to an increase in absolute pressure.
The term “tissue site” as used herein refers to a wound or defect located on or within any tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. The term “tissue site” may further refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it is desired to add or promote the growth of additional tissue. For example, reduced pressure tissue treatment may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
Referring to
Distribution manifold 122 may also be constructed from bioresorbable materials that do not need to be removed from a patient's body following use of reduced pressure treatment system 100. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, polyhydroxybutarates, polyhydroxyvalerates, polysaccharides, polyaminoacids, and capralactones. Distribution manifold 122 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with distribution manifold 122 to promote cell-growth. A scaffold is a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials. In one example, the scaffold material has a high void-fraction (i.e., a high content of air).
The distribution manifold 122 is fluidly connected to the reduced pressure source 134 by a conduit 112. The conduit 112 may fluidly communicate with the distribution manifold 122 through a tubing adapter 118 positioned adjacent to the distribution manifold 122. A drape 128 may be placed over the distribution manifold 122 and sealed around a perimeter of the tissue site 108 to maintain reduced pressure at the tissue site 108.
In the embodiment illustrated in
Referring still to
A pressure regulator 148 may be fluidly connected between the compressible bladder system 138 and the canister 142 to regulate and control the amount of pressure delivered to the canister 142 and the tissue site 108. The pressure regulator may be any device that is capable of regulating or controlling a reduced pressure or a positive pressure. In one embodiment, the pressure regulator 148 is provided to ensure that the reduced pressure delivered to the tissue site 108 does not exceed a threshold amount. In other words, the pressure regulator ensures that the absolute pressure supplied to the tissue site 108 is not too low. A vent (not shown) may be associated with the pressure regulator 148 to raise the absolute pressure within the pressure regulator if more reduced pressure than is needed is provided by the compressible bladder system 138. The vent may operate by allowing ambient air into the pressure regulator when the absolute pressure within the pressure regulator 148 drops below a predetermined value.
In addition to the canister 142 and pressure regulator 148, the reduced pressure treatment system 100 may also include sensors, processing units, alarm indicators, memory, databases, software, display units, and user interfaces that further facilitate the application of reduced pressure treatment to the tissue site 108. In one example, a sensor (not shown) may be disposed at or near the reduced pressure source 134 to determine a source pressure generated by the reduced pressure source 134. The sensor may communicate with a processing unit that monitors and controls the reduced pressure that is delivered by the reduced pressure source 134.
Referring to
The chamber 218 of each compressible bladder 210 includes an inlet 230 and an outlet 234. An inlet valve 240 is in fluid communication with the inlet 230 to prevent fluid exiting the chamber 218 from passing through the inlet 230. An outlet valve 244 is in fluid communication with the outlet 234 to prevent fluid from entering the chamber 218 through the outlet 234. The inlet valve 240 and outlet valve 244 may be positioned in conduits fluidly connected to the inlet 230 and outlet 234, respectively, as shown in
Referring still to
The positioning of the compressible bladders 210 under the heel region 314 and forefoot region 318 of the foot 310 allows a more consistent application of reduced, pressure as the user cyclically applies weight to the heel region 314 and then to the forefoot region 318. Such a regimen of weight distribution is consistent with normal walking or running activities, and the compressible bladder system 138 is particularly suited for generating reduced pressure while a user is walking or running. As the user distributes weight to the heel region 314, the compressible bladder 210 under the heel region 314 compresses to the compressed position. As the user's weight shifts to the forefoot region 318, the compressible bladder 210 under the forefoot region 318 compresses to the compressed position. The shifting of weight to the forefoot region 318 relieves the compressive force on the compressible bladder 210 near the heel region 314, thereby allowing the compressible bladder 210 under the heel region to expand and generate reduced pressure. When the user's weight shifts back to the heel region 314, the compressible bladder 210 under the forefoot region 318 expands, thereby generating reduced pressure. This cycle continues as the user continues walking, which permits a generation of reduced pressure.
Referring to
The chamber 418 of each compressible bladder 410 includes an inlet 430 and an outlet 434. An inlet valve 440 is in fluid communication with the inlet 430 to prevent fluid exiting the chamber 418 from passing through the inlet 430. An outlet valve 444 is in fluid communication with the outlet 434 to prevent fluid from entering the chamber 418 through the outlet 434. The inlet valve 440 and outlet valve 444 may be positioned in conduits fluidly connected to the inlet 430 and outlet 434, respectively, as shown in
In the embodiment illustrated in
Each of the cavities 464, 468 includes an outlet (not shown) and a one-way valve (not shown) so that air or other gases within the cavities 464, 468 may be expelled from the cavities 464, 468 when the piston wall 472 is moved to a retracted position. A user may place the piston wall 472 in the retracted position by exerting a compressive force on the piston wall.
The outlet 434 of each compressible bladder 410 is fluidly connected to the first variable-volume cavity 464. When the piston wall 472 has been positioned in the retracted position, the positively pressured gas from the outlet 434 may bias the piston wall 472 toward the extended position (see
Referring to
The article of footwear 508 may be an offloading boat, cast walker, neuropathic walker, or any other type of orthotic or therapeutic footwear. The article of footwear 508 is particularly well suited, when equipped with the compressible bladder system 512 to treat diabetic foot ulcers and other foot-related injuries and wounds. The article of footwear 508 may be designed to relieve pressure in injured areas of the foot of a patient, thereby allowing the patient to remain ambulatory. As the patient walks, the compressible bladder system 512 is activated as previously described to generate reduced pressure. This reduced pressure may be directed to the injuries or wounds of the patient to improve healing through reduced pressure treatment.
A method for providing a reduced pressure to a reduced pressure tissue treatment system used by a user is provided. The method includes compressing a compressible bladder with a foot of the user, and generating the reduced pressure within a chamber of the compressible bladder as the compressible bladder expands. The compressible bladder may be similar to any of the compressible bladders or compressible bladder systems described herein. In one embodiment, the method may further include compressing a second compressible bladder with the foot of the user and generating a second reduced pressure within a second chamber of the second compressible bladder as the second compressible bladder expands. The second reduced pressure may be substantially the same as the first reduced pressure, or alternatively may be a higher or lower pressure. When two compressible bladders are provided, the first compressible bladder is positioned under a forefoot region of the foot and is compressed when the user places weight on the forefoot region. The second compressible bladder is positioned under a heel region of the foot and is compressed when the user places weight on the heel region. In this manner, both of the compressible bladders are compressed and expanded during a single stride of the user while walking.
While the compressible bladders described herein are positionable beneath a foot of a user, the compressible bladders may instead be compressed by applying a force from another part of the body or some other object. Additionally, while a compressible bladder system having two compressible bladders is illustrated, a single compressible bladder may be used, or alternatively, multiple compressible bladders in excess of two may be used. In one illustrative embodiment, when multiple compressible bladders are used, each of the compressible bladders is fluidly independent, and each compressible bladder includes one-way valves or devices associated with the inlet and outlet of the compressible bladder.
The pressure regulators described herein may serve to regulate or control the pressure supplied by the compressible bladder system. With respect to pressure regulator 460, the pressure regulator may further be used to provide a reduced pressure to a tissue site when a positive pressure is supplied to the pressure regulator. While the use of pressure regulators may be preferred in some embodiments, in other embodiments, a pressure regulator may be omitted. In these embodiments that do not include a separate pressure regulator, the compressible bladder may be configured to be self-regulating based on the sizing, shape, and material used for the compressible bladder and the biasing member. For example, in one embodiment, as the reduced pressure at the tissue site and in the conduit leading to the tissue site increases, the compressible bladder continues to supply additional reduced pressure as long as the resiliency of the biasing member or the chamber wall of the compressible bladder is able to overcome the tendency of the compressible bladder to remain collapsed. When the biasing member or chamber wall is no longer able to expand following compression due to the amount of reduced pressure in the conduit leading to the tissue site, the compressible bladder will no longer generate additional reduced pressure.
It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.
This application is a continuation of U.S. Non-Provisional application Ser. No. 12/403,911 filed Mar. 13, 2009 which claims the benefit of U.S. Provisional Application No. 61/036,391 filed Mar. 13, 2008, which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3809087 | Lewis, Jr. | May 1974 | A |
3826254 | Mellor | Jul 1974 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielsen | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5348530 | Grim | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5934888 | Marka et al. | Aug 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6241747 | Ruff | Jun 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
7051456 | Swigart et al. | May 2006 | B2 |
7553306 | Hunt et al. | Jun 2009 | B1 |
8366644 | Coward et al. | Feb 2013 | B2 |
20010029956 | Argenta et al. | Oct 2001 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20020183652 | Kensey | Dec 2002 | A1 |
20030153857 | McCarthy | Aug 2003 | A1 |
20040010939 | Liu et al. | Jan 2004 | A1 |
20040163278 | Caspers | Aug 2004 | A1 |
20090124988 | Coulthard | May 2009 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Apr 1999 | AU |
455496 | Feb 2002 | AU |
2005436 | Jun 1990 | CA |
2120585 | Nov 1992 | CN |
1848689 | Mar 1962 | DE |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Oct 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1018967 | Aug 2004 | EP |
692578 | Jun 1953 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 333 965 | Aug 1999 | GB |
2 329 127 | Aug 2000 | GB |
4129536 | Apr 1992 | JP |
10-061546 | Mar 1998 | JP |
11-42101 | Feb 1999 | JP |
2006-116162 | May 2006 | JP |
71559 | Apr 2002 | SG |
8002182 | Oct 1980 | WO |
8704626 | Aug 1987 | WO |
9010424 | Sep 1990 | WO |
9309727 | May 1993 | WO |
9420041 | Sep 1994 | WO |
9605873 | Feb 1996 | WO |
9635401 | Nov 1996 | WO |
9718007 | May 1997 | WO |
9913793 | Mar 1999 | WO |
Entry |
---|
Written Opinion from Hungarian Patent Office for Corresponding Singapore Application 201006142-2 dated Apr. 9, 2013. |
Communication under Rule 71(3) EPC for corresponding European Application No. 12160-678, 5 pages, dated May 20, 2015. |
N. A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modem Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96. |
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 563-576. |
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
Dattilo, Philip P., JR., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu. A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
K.F. Jeter, T.E. Tintle, and M. Chariker, Managing Draining Wounds and Fistulae: “New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {hacek over (Z)}ivadinovic, V. ukić, {hacek over (Z)}. Maksimović, . Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164. |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.A. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
V.A.C. ® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007). |
Number | Date | Country | |
---|---|---|---|
20130116661 A1 | May 2013 | US |
Number | Date | Country | |
---|---|---|---|
61036391 | Mar 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12403911 | Mar 2009 | US |
Child | 13728712 | US |